Pharmacovigilance of antimalarial treatment in Africa: is it possible?
2006
Pharmacovigilance of Antimalarial Treatment in Africa
publication
Evidence: moderate
Author Information
Author(s): Talisuna Ambrose O, Staedke Sarah G, D'Alessandro Umberto
Hypothesis
Is it possible to establish pharmacovigilance systems for antimalarial treatments in Africa?
Conclusion
Establishing pharmacovigilance systems for antimalarial treatments in Africa is essential but challenging due to inadequate infrastructure and limited resources.
Supporting Evidence
- Pharmacovigilance is critical for evaluating safety risks of antimalarial drugs.
- Many African countries have adopted artemisinin-based combination therapy as first-line treatment for malaria.
- Informal use of antimalarial drugs increases the risk of incorrect dosing and inappropriate treatment.
Takeaway
This study talks about keeping track of how safe antimalarial medicines are in Africa, which is important because many people use them, but there are challenges in doing this.
Limitations
Inadequate infrastructure and limited resources in developing countries pose challenges to implementing pharmacovigilance.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website